Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study

Autor: Liberata Sportiello, Annalisa Capuano, Claudia Pagliaro, Magnus T. Jensen, Daniel Bech Rasmussen, Kristian Kragholm, Maurizio Sessa, Francesco Rossi, Morten Andersen, Annamaria Mascolo, Concetta Rafaniello, Giuseppe Michele Tari
Přispěvatelé: Sessa, M., Mascolo, A., Rasmussen, D. B., Kragholm, K., Jensen, M. T., Sportiello, L., Rafaniello, C., Tari, G. M., Pagliaro, C., Andersen, M., Rossi, F., Capuano, A.
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
Epidemiology
lcsh:Medicine
Comorbidity
Nebivolol
Cohort Studies
Pulmonary Disease
Chronic Obstructive

0302 clinical medicine
Registries
lcsh:Science
Atrioventricular Block
Carvedilol
Metoprolol
Aged
80 and over

COPD
Multidisciplinary
Drug Substitution
Hospitalization
Italy
Bisoprolol
Practice Guidelines as Topic
Female
Interventional cardiology
medicine.drug
medicine.medical_specialty
medicine.drug_class
Adrenergic beta-Antagonists
Drug Prescriptions
Article
03 medical and health sciences
Internal medicine
medicine
Humans
Renal Insufficiency
Chronic

Beta blocker
Aged
Retrospective Studies
Heart Failure
business.industry
lcsh:R
Thrombosis
Odds ratio
medicine.disease
Drug Utilization
Cerebrovascular Disorders
030104 developmental biology
Heart failure
lcsh:Q
business
030217 neurology & neurosurgery
Zdroj: Sessa, M, Mascolo, A, Rasmussen, D B, Kragholm, K, Jensen, M T, Sportiello, L, Rafaniello, C, Tari, G M, Pagliaro, C, Andersen, M, Rossi, F & Capuano, A 2019, ' Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease : an Italian register-based cohort study ', Scientific Reports, vol. 9, no. 1, 11465 . https://doi.org/10.1038/s41598-019-47967-y
Sessa, M, Mascolo, A, Rasmussen, D B, Kragholm, K, Jensen, M T, Sportiello, L, Rafaniello, C, Tar, G M, Pagliaro, C, Andersen, M, Rossi, F & Capuano, A 2019, ' Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease : an Italian register-based cohort study ', Scientific Reports, vol. 9, no. 1, 11465, pp. 11465 . https://doi.org/10.1038/s41598-019-47967-y
Sessa, M, Mascolo, A, Rasmussen, D B, Kragholm, K, Jensen, M T, Sportiello, L, Rafaniello, C, Tari, G M, Pagliaro, C, Andersen, M, Rossi, F & Capuano, A 2019, ' Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease : an Italian register-based cohort study ', Scientific Reports, vol. 9, 11465 . https://doi.org/10.1038/s41598-019-47967-y
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-8 (2019)
ISSN: 2045-2322
DOI: 10.1038/s41598-019-47967-y
Popis: Clinical guidelines suggest that for patients with heart failure and concurrent chronic obstructive pulmonary disease (COPD), metoprolol/bisoprolol/nebivolol should be preferred over carvedilol. However, studies suggest a high proportion of carvedilol usage that remains unexplained. Therefore, we aimed to investigate the predictors of carvedilol choice in patients with heart failure and COPD that were naïve to carvedilol or metoprolol/bisoprolol/nebivolol. Caserta Local Health Unit databases (Italy) were used as data sources. Age, sex, chronic/acute comorbidities, and co-medications were included in a logistic regression model to assess predictors of carvedilol choice. Chronic comorbidities include those defined in the Elixhauser comorbidity index and all hospitalizations within two years prior to the first beta-blocker prescription. Comedications include all redeemed prescriptions within one year prior to the beta-blocker prescription. Kernel density estimations were used to assess the overlap in propensity and preference scores distributions for receiving carvedilol and thereby potential beta-blocker exchangeability. Totally, 10091 patients composed the study population; 2011 were exposed to carvedilol. The overlapping of propensity scores distributions was 57%. Accordingly, the exchangeability was not reached. Atrioventricular block (Odds Ratio, OR 8.20; 95% Confidence Interval, 95% CI 1.30–51.80), cerebrovascular thrombosis (OR 7.06; 95% CI 1.14–43.68), chronic kidney disease (OR 4.32; 95% CI 1.16–16.02), and acute heart failure (OR 1.97; 95% CI 1.28–3.03) hospitalizations were statistically significantly associated with carvedilol choice. Analogously, human insulin (OR 3.00; 95% CI 1.24–7.24), fondaparinux (OR 2.47; 95% CI 1.17–5.21) or strontium ranelate (OR 2.03; 95% CI 1.06–3.90) redeemed prescriptions. In conclusion, this study suggests the absence of beta-blockers exchangeability and a preferential choice of carvedilol in patients with heart failure, COPD and concurrent chronic kidney disease, atrioventricular block, cerebrovascular thrombosis, acute heart failure or redeeming human insulin, fondaparinux or strontium ranelate prescriptions. Therefore, it suggests that choice of prescribing carvedilol over metoprolol/bisoprolol/nebivolol is driven by differences in comorbidities and co-treatments.
Databáze: OpenAIRE